Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Europe
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Americas
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Emerging Markets
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Mature Markets
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Middle East & Africa
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Asia Pacific
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Colorectal Cancer – Unmet Need – Unmet Need – Previously treated BRAF-mutant or RAS-mutant metastatic colorectal cancer (US/EU)
The treatment landscape for second- and later-line metastatic colorectal cancer with BRAF or RAS mutations is rapidly changing following the market entry of biomarker-specific combination therapies…
Wet Age-related Macular Degeneration – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key wet AMD patient populations, covering 171 countries and more than 99…
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and topical steroids. Although these therapies can alleviate EoE symptoms, their remission…
Non-Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Non-Small-Cell Lung Cancer (US)
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi…
